Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 19/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | HMGCR | P04035 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077308 | 0.88 | GCGR (0.67) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL13302217 | 0.87 | GCGR (0.63) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL7720729 | 0.87 | GCGR (0.86) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL12074145 | 0.86 | GCGR (0.66) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL13302216 | 0.86 | GCGR (0.62) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL12215998 | 0.85 | ESR1 (0.67) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL22894610 | 0.85 | GCGR (0.76) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL2648452 | 0.85 | GCGR (1.00) | GCGR | |
| SCHEMBL3445407 | 0.84 | GCGR (0.78) | GCGRESR1HMGCRCHRM1TBXA2R | |
| SCHEMBL7561153 | 0.83 | ESR1 (0.62) | GCGRESR1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116399-A1 | Tumor Homing Statin Derivatives | Da Zen Theranostics, Inc. (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3763389-A1 | TUMOR HOMING STATIN DERIVATIVES | Da Zen Theranostics Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2013083718-A1 | PROCESS FOR THE PREPARATION OF A STATIN PRECURSOR | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116399-A1 | Tumor Homing Statin Derivatives | HMGCR, DHCR7, DHODH | GCGR 3187/4885ESR1 1716/4885HMGCR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.